Sirius Genomics Announces Issuance of U.S. Patent

By Sirius Genomics Inc., PRNE
Monday, October 25, 2010

VANCOUVER, October 26, 2010 - Sirius Genomics, a developer of companion diagnostics, announced today
that U.S. Patent No. 7,820,376 entitled "Protein C Polymorphisms" has been
issued by the United States Patent and Trademark Office. The patent relates
to a novel use of a Single Nucleotide Polymorphism (SNP) located in the
Protein C gene.

"The patent covers methods of predicting outcome or prognosis in sepsis,
and other related conditions, by determining a subject's genotype at the SNP.
This patent issuance further strengthens Sirius' patent portfolio and
position as a developer of companion diagnostics," stated Dr. Jennifer
, Vice President, Intellectual Property at Sirius Genomics.

"Sirius Genomics' steadily expanding patent estate stems from discoveries
made from the Company's focused approach in the identification and validation
of genetic markers linked to drug response. Our focus is on improving
outcomes for patients treated with various classes of drugs used in the acute
care setting," stated Chris Wagner, President and CEO of Sirius Genomics.

Sirius' intellectual property portfolio includes patent families related
to several therapies available and under development for sepsis and other
acute conditions.

About Sirius Genomics:

Sirius Genomics develops companion diagnostics (CDx) that are closely
tied to therapeutic decisions, leading to better patient outcomes through
personalized medicine. Sirius generates value by improving the safety and
effectiveness of pharmaceutical compounds. The Company correlates patient
genetics with clinical outcomes, leading to proprietary and commercially
viable CDx products that enable better drug treatment. The Company's first
product is a genetic predictor of response to treatment for sepsis, a severe
blood infection. Learn more at

This release contains forward-looking statements that are not based on
historical fact. These forward-looking statements involve risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from those expressed or implied by
such forward-looking statements. Readers are cautioned not to place undue
reliance on such forward-looking statements.

    For further information:

    Chris Wagner
    President and CEO
    Sirius Genomics

For further information: Chris Wagner, President and CEO, Sirius Genomics, +1-604-484-7195

will not be displayed